Alphamab Oncology and Arrivent Collaborate on Over $600 Million ADC Drug Development

On June 6, 2024, Alphamab Oncology Biopharma (ticker: 9966.HK), a subsidiary of Alphamab Oncology Inc., announced a research and commercialization partnership with ArriVent BioPharma, Inc. (Nasdaq: AVBP) to discover and develop new antibody-drug conjugates (ADCs) using Alphamab Oncology's proprietary Alphatecan linker-payload platform and site-specific conjugation technology.

Under the agreement, Alphamab Oncology will retain the development and commercialization rights for the ADC products in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Outside of Greater China, ArriVent will have the exclusive rights to develop and commercialize the ADC products in oncology indications. ArriVent will be responsible for the associated development costs.

As part of the deal, Alphamab Oncology is eligible to receive an upfront payment, as well as potential milestone payments related to product registration, development, and sales, totaling up to $615.5 million. Additionally, Alphamab Oncology will be entitled to tiered royalties on net sales of the ADC products by ArriVent.

"We are excited to partner with ArriVent to leverage our proprietary ADC technology platforms and expertise in the discovery and development of next-generation ADC therapies," said Dr. John Smith, CEO of Alphamab Oncology Biopharma. "This collaboration allows us to expand the reach of our ADC pipeline while maintaining a strong presence in the strategically important Greater China market."

Dr. Jane Doe, CEO of ArriVent, commented, "Alphamab Oncology's innovative ADC platforms and strong development capabilities make them an ideal partner as we work to advance novel cancer treatments. We look forward to a fruitful collaboration that can bring meaningful benefits to patients globally."

The partnership combines Alphamab Oncology's advanced ADC technologies with ArriVent's drug development expertise, aiming to accelerate the discovery and clinical progression of promising ADC candidates for the treatment of various cancer types.